Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBITDA Margin (2016 - 2025)

CorMedix (CRMD) has disclosed EBITDA Margin for 14 consecutive years, with 0.07% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 7.0% to 0.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.03% through Dec 2025, down 2.0% year-over-year, with the annual reading at 0.03% for FY2025, 2.0% down from the prior year.
  • EBITDA Margin hit 0.07% in Q4 2025 for CorMedix, down from 0.01% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 192858.54% in Q2 2023 to a low of 100446.94% in Q3 2022.
  • Historically, EBITDA Margin has averaged 1581.72% across 5 years, with a median of 0.02% in 2025.
  • Biggest five-year swings in EBITDA Margin: surged 22868991bps in 2023 and later tumbled -19285826bps in 2024.
  • Year by year, EBITDA Margin stood at 13829.39% in 2021, then tumbled by -99bps to 27513.23% in 2022, then surged by 370bps to 74358.67% in 2023, then tumbled by -100bps to 0.01% in 2024, then tumbled by -1137bps to 0.07% in 2025.
  • Business Quant data shows EBITDA Margin for CRMD at 0.07% in Q4 2025, 0.01% in Q3 2025, and 0.01% in Q2 2025.